• Publications
  • Influence
Secukinumab in plaque psoriasis--results of two phase 3 trials.
TLDR
Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
TLDR
Bdalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis, and was found to be superior to placebo at week 12 with respect to a 100% reduction in PASI score (PASI 100).
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
TLDR
Briakinumab showed higher efficacy than methotrexate in patients with moderate-to-severe psoriasis, and serious infections and cancers occurred more frequently with briakinumabs, but the differences were not significant.
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
TLDR
Extended exposure to 50 mg of etanercept twice weekly resulted in exposure-adjusted rates of adverse events and infections similar to those in patients receiving placebo, and improvements in physician- and patient-reported measures of psoriasis severity were observed for up to 96 weeks of continuous etanerscept therapy.
...
...